Imovax Polio Associação (Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po)

Imovax Polio is an inactivated poliovirus vaccine used to prevent infection by poliovirus types 1, 2 and 3.

• Poliomyelitis: provides active immunity that prevents the development of paralytic disease.
• International travel to endemic areas: protects travelers from acquiring polio infection.
• Outbreak response: enables mass immunization campaigns to control community spread.
• Routine childhood immunization: contributes to herd immunity in national vaccination programs.

• Imovax Polio contains chemically inactivated whole poliovirus particles of types 1, 2 and 3. After intramuscular or subcutaneous injection, the viral antigens are taken up by antigen‑presenting cells, stimulating B‑cell production of neutralizing antibodies and activating T‑cell helper responses. The resulting humoral immunity blocks viral attachment and replication, thereby preventing poliovirus infection and subsequent paralytic disease.

Adverse reactions to Imovax Polio are generally mild and transient, reflecting the body’s immune response to the vaccine.

Common Side Effects

• Injection site pain: mild soreness at the site of administration.
• Redness or swelling: localized erythema or edema.
• Fever: low‑grade temperature rise within 24‑48 hours.
• Headache: transient headache following vaccination.
• Fatigue: temporary feeling of tiredness.
• Myalgia: mild muscle aches.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Guillain‑Barré syndrome: rare autoimmune neuropathy with progressive weakness.
• Seizures: infrequent convulsive episodes post‑vaccination.
• Severe hypotension: marked drop in blood pressure after injection.

Before administering Imovax Polio, healthcare professionals should consider several precautionary measures to ensure safe use.

• Pregnancy: safety data are limited; vaccinate only if benefits outweigh potential risks.
• Breastfeeding: limited information; continue breastfeeding while monitoring infant.
• Immunocompromised patients: vaccine is inactivated and generally safe, but immune response may be reduced.
• Known allergy: avoid if the patient has hypersensitivity to any vaccine component.
• Concomitant vaccines: may be given with other vaccines according to schedule, but observe for combined reactogenicity.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imovax Polio may interact with other agents that affect the immune system or vaccine efficacy.

Major Interactions (Avoid)

• Live attenuated vaccines: avoid simultaneous administration to prevent interference with immune response.
• Blood products containing immunoglobulins: may neutralize vaccine antigens if given concurrently.

Moderate Interactions (Monitor Closely)

• Immunosuppressive therapy: may diminish antibody production, requiring serologic monitoring.
• Antipyretic medications: can mask post‑vaccination fever, affecting assessment of reactogenicity.
• Other injectable vaccines: schedule spacing may be needed to reduce local reactogenicity.